Early-phase clinical trial to test new CAR T-cell therapy for multiple myeloma

Center for Cancer Research investigators led by James Kochenderfer, M.D., of the Experimental Transplantation and Immunology Branch, are conducting a clinical trial to test a new chimeric antigen receptor (CAR) T-cell therapy in patients whose multiple myeloma has persisted or relapsed despite standard therapy. Their goal is to develop a CAR T-cell therapy that provides lasting remission of a disease that remains highly resistant to current treatments. Read more...

Rosenberg accepting award

Steve Rosenberg receives the 2018 Jacobson Innovation Award of the American College of Surgeons

Jun 12, 2018

The 2018 Jacobson Award of the American College of Surgeons (ACS) was presented to Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, at a dinner held in his honor on June 8 in Chicago. According to the ACS press release, the prestigious award honors living surgeons who have been innovators of a new development or technique in any field of surgery. Dr. Rosenberg was honored with this international surgical award for his role in developing effective immunotherapies and gene therapies for patients with advanced cancers. Read more...

Steve Rosenberg receives the 2018 Jacobson Innovation Award of the American College of Surgeons
CBS news logo

Steve Rosenberg featured in CBS News story profiling an immunotherapy clinical trial patient

Jun 11, 2018

When standard treatment failed to eliminate her late-stage breast cancer, Judy Perkins turned to a clinical trial led by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the Center for Cancer Research. The trial uses a novel immunotherapy approach of multiplying specific cancer-fighting cells and injecting them into a patient’s bloodstream to kill the cancer. In a recent interview with CBS News’ Jonathan LaPook, Perkins — who remains cancer free more than two years later — shares her clinical trial experience.  Read more...

Steve Rosenberg featured in CBS News story profiling an immunotherapy clinical trial patient
Cell division in breast cancer

Committing to cell division may be clue to cancer cell growth

Jun 6, 2018

In a new study in Nature, CCR researchers describe, for the first time, how a cell commits to dividing during the cell cycle. Since cancer cells divide when they should not, targeting this pathway might stop their inappropriate growth. Read more...

Tumor cell

Antibody-linked drug shrinks various types of tumors in preclinical study

Jun 5, 2018

A preclinical study by Center for Cancer Research investigators and colleagues shows that a drug guided by an attached target-seeking antibody can recognize cells infiltrating tumors, the tumor stroma, and cause various types of tumors to shrink, and in many cases, disappear. Their findings suggest that when stromal cells take up the ADC, they cleave the drug from the antibody and release it to kill neighboring tumor cells. Read more...

Breast cancer scan

Findings from clinical trial led by Steve Rosenberg published in Nature Medicine

Jun 4, 2018

Findings from a clinical trial led by Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, were recently published in Nature Medicine. The ongoing phase II trial explores a novel approach to immunotherapy that led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. Using a modified form of adoptive cell transfer, investigators aim to target tumor cell mutations to shrink tumors in patients with common epithelial cancers. According to Dr. Rosenberg, “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many cancer types.”  Read more...

Findings from clinical trial led by Steve Rosenberg published in Nature Medicine
Sarah and family

Fighting a rare central nervous system tumor with research and optimism

Jun 1, 2018

In January 2016, Sarah Rosenfeld had such severe pain shooting down her legs she couldn’t walk, sleep or care for her young daughters. After weeks of physical therapy for what she thought was sciatica, she had an MRI. Thirty-seven-year-old Rosenfeld learned she had something far worse: myxopapillary ependymoma, a rare cancerous tumor in her spinal cord. She came to the NIH for treatment options and enrolled in a clinical trial with Mark Gilbert, M.D., Chief of the Neuro-Oncology Branch at the Center for Cancer Research. Read more...

Doug Lowy

Doug Lowy receives ASCO Science of Oncology Award and Lecture

Jun 1, 2018

Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology, has received the 2018 Science of Oncology Award and Lecture from the American Society of Clinical Oncology (ASCO). According to ASCO, this annual award is given in recognition of a recipient’s outstanding contributions to basic or translational research in cancer. Along with receiving an honorarium, commemorative plagque and support to attend the ASCO Annual Meeting held June 1-5, 2018 in Chicago, Dr. Lowy will deliver a 30-minute lecture, “Preventing HPV-Associated Cancers by Vaccination” during the plenary session on Sunday, June 3.  Read more...

Doug Lowy receives ASCO Science of Oncology Award and Lecture
Lipogenesis in Prostate Cancer

Combination therapy for biochemically recurrent prostate cancer tested in new trial

May 31, 2018

Prostate-specific antigen (PSA) is an enzyme released by the prostate gland and is found in abnormally high concentrations in the blood of men with prostate cancer. “Biochemical recurrence” is when PSA levels continue to rise after initial treatment for prostate cancer, such as surgery or radiation. Marijo Bilusic, M.D., of the Genitourinary Malignancies Branch is leading the Center for Cancer Research’s effort in a study to treat men with biochemically recurrent prostate cancer with a combination drug therapy. Read more...

ASCO logo

CCR researchers receive ASCO Annual Meeting Merit Awards

May 30, 2018

The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation recently announced the recipients of the 2018 ASCO Annual Meeting Merit Awards. Among those receiving the awards are CCR researchers Andrea Gross, M.D., Clinical Fellow in the Pediatric Oncology Branch and Jack Shern, M.D., Assistant Clinical Investigator in the Pediatric Oncology Branch. Dr. Gross will receive the Bradley Stuart Beller Endowed Merit Award for the highest ranking abstract at an ASCO scientific meeting, and Dr. Shern will receive the James B. Nachman Endowed ASCO Junior Faculty Award in Pediatric Oncology. All recipients will be recognized at the 2018 ASCO Annual Meeting held June 1-5 in Chicago.  Read more...

CCR researchers receive ASCO Annual Meeting Merit Awards
VHL

25 years ago: CCR scientists discover first gene linked to kidney cancer

May 29, 2018

Twenty-five years ago, NCI scientists uncovered the VHL gene, a gene whose mutation can lead to the development of kidney tumors. The discovery, the result of a decade-long partnership between CCR scientists, including W. Marston Linehan, M.D., Chief of CCR’s Urologic Oncology Branch, and families affected by the disease, paved the way for new targeted therapies that have improved the prognosis for patients with advanced kidney cancers.  Read more...

Pages